---
audienceLevel: patient
cancerTypes:
- gi neuroendocrine tumors
- colorectal
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- cancer-type
title: Gastrointestinal Neuroendocrine Tumors Research - NCI
url: https://www.cancer.gov/types/gi-neuroendocrine-tumors/research
version: v1
---

# Gastrointestinal Neuroendocrine Tumors Research - NCI

# Gastrointestinal Neuroendocrine Tumors Research

- [Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine Tumors](/news-events/cancer-currents-blog/2024/lutathera-neuroendocrine-tumor-initial-treatment)

Posted: March 1, 2024

Adding Lu 177-dotate to the initial treatment of certain advanced neuroendocrine tumors nearly tripling the length of time people survive without their tumors getting worse, according to new clinical trial results.
- [Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows](/news-events/cancer-currents-blog/2018/appendix-cancer-genetic-distinct)

Posted: September 12, 2018

The largest-ever study of DNA changes in appendix cancer shows that it is distinct from colorectal and other gastrointestinal cancers and suggests that specific mutations in appendix tumors may help predict whether they may be aggressive.
- [FDA Approves New Treatment for Certain Neuroendocrine Tumors](/news-events/cancer-currents-blog/2018/lutathera-fda-gastrointestinal-nets)

Posted: February 8, 2018

People with cancerous neuroendocrine tumors (NETs) that affect the digestive tract now have a new treatment option. On January 29, FDA approved the targeted treatment lutetium Lu 177 dotatate (LutatheraÂ®) for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract.
